Sangamo Therapeutics Statistics
Total Valuation
SGMO has a market cap or net worth of $235.77 million. The enterprise value is $224.30 million.
Important Dates
The next estimated earnings date is Wednesday, March 12, 2025, before market open.
| Earnings Date | Mar 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SGMO has 208.65 million shares outstanding. The number of shares has increased by 13.03% in one year.
| Current Share Class | 208.65M |
| Shares Outstanding | 208.65M |
| Shares Change (YoY) | +13.03% |
| Shares Change (QoQ) | +5.09% |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 24.40% |
| Float | 204.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.18 |
| Forward PS | 4.80 |
| PB Ratio | 6.02 |
| P/TBV Ratio | 6.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.35 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -154.94% and return on invested capital (ROIC) is -64.79%.
| Return on Equity (ROE) | -154.94% |
| Return on Assets (ROA) | -46.35% |
| Return on Capital (ROIC) | -64.79% |
| Revenue Per Employee | $129,114 |
| Profits Per Employee | -$332,938 |
| Employee Count | 405 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -12,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +158.04% in the last 52 weeks. The beta is 1.30, so SGMO's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | +158.04% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 36.43 |
| Average Volume (20 Days) | 10,139,077 |
Short Selling Information
The latest short interest is 21.52 million, so 10.31% of the outstanding shares have been sold short.
| Short Interest | 21.52M |
| Short Previous Month | 19.61M |
| Short % of Shares Out | 10.31% |
| Short % of Float | 10.55% |
| Short Ratio (days to cover) | 1.92 |
Income Statement
In the last 12 months, SGMO had revenue of $52.29 million and -$134.84 million in losses. Loss per share was -$0.70.
| Revenue | 52.29M |
| Gross Profit | -77.56M |
| Operating Income | -122.72M |
| Pretax Income | -248.51M |
| Net Income | -134.84M |
| EBITDA | -117.03M |
| EBIT | -122.72M |
| Loss Per Share | -$0.70 |
Full Income StatementBalance Sheet
The company has $39.20 million in cash and $27.73 million in debt, giving a net cash position of $11.47 million or $0.05 per share.
| Cash & Cash Equivalents | 39.20M |
| Total Debt | 27.73M |
| Net Cash | 11.47M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 39.13M |
| Book Value Per Share | 0.19 |
| Working Capital | 14.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$114.33 million and capital expenditures -$2.79 million, giving a free cash flow of -$117.11 million.
| Operating Cash Flow | -114.33M |
| Capital Expenditures | -2.79M |
| Free Cash Flow | -117.11M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
Gross margin is -148.33%, with operating and profit margins of -234.69% and -257.86%.
| Gross Margin | -148.33% |
| Operating Margin | -234.69% |
| Pretax Margin | -257.89% |
| Profit Margin | -257.86% |
| EBITDA Margin | -223.80% |
| EBIT Margin | -234.69% |
| FCF Margin | n/a |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.03% |
| Shareholder Yield | -13.03% |
| Earnings Yield | -57.19% |
| FCF Yield | -49.67% |
Analyst Forecast
The average price target for SGMO is $5.20, which is 360.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.20 |
| Price Target Difference | 360.18% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 19.62% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SGMO has an Altman Z-Score of -20.65 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.65 |
| Piotroski F-Score | 1 |